Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

The purpose of this study was to investigate the reason that diabetic retinopathy (DR) is delayed from the onset of diabetes (DM) in diabetic mice. To this end, we tested the hypothesis that the deleterious effects of DM are initially tolerated because endogenous antioxidative defense is elevated and thereby confers resistance to oxidative stress-induced death. We found that this was indeed the case in both type 1 DM (T1D) and type 2 DM (T2D) mouse models. The retinal expression of antioxidant defense genes was increased soon after the onset of DM. In addition, ischemia/oxidative stress caused less death in the retinal vasculature of DM versus non-DM mice. Further investigation with T1D mice revealed that protection was transient; it waned as the duration of DM was prolonged. Finally, a loss of protection was associated with the manifestation of both neural and vascular abnormalities that are diagnostic of DR in mice. These observations demonstrate that DM can transiently activate protection from oxidative stress, which is a plausible explanation for the delay in the development of DR from the onset of DM.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10341443PMC
http://dx.doi.org/10.3390/ijms241310869DOI Listing

Publication Analysis

Top Keywords

diabetic retinopathy
8
slow progression
4
progression diabetic
4
retinopathy associated
4
associated transient
4
protection
4
transient protection
4
protection retinal
4
retinal vessels
4
vessels death
4

Similar Publications

Abtract: PURPOSE: To evaluate the correlation between corneal backscatter and visual function in patients with Fuchs endothelial corneal dystrophy (FECD).

Study Design: Prospective case series.

Methods: This study included 53 eyes from 38 patients with FECD.

View Article and Find Full Text PDF

"Characterization of visual function parameters in relation to macular pigment optical density in a pediatric population".

Graefes Arch Clin Exp Ophthalmol

September 2025

Department of Physics of Condensed Matter, Optics Area. Vision Research Group (CIVIUS), University of Seville, Avenida de la Reina Mercedes s/n (41012), Seville, Spain.

Purpose: To analyze the relationship between various visual function parameters (refractive status, visual acuity and contrast sensitivity) and macular pigment optical density (MPOD) values, as well as dietary intake of lutein and zeaxanthin in a pediatric population.

Methods: Thirty-six healthy White pediatric patients participated in this cross-sectional study conducted at the Optometry Clinic (Faculty of Pharmacy, Seville, Spain). MPOD values were measured using the MPSII (Macular Pigment Screener II).

View Article and Find Full Text PDF

Cost-benefit analysis of screening programme for diabetic retinopathy in Bulgaria.

Br J Clin Pharmacol

September 2025

Department of Organization and Economics of Pharmacy, Faculty of Pharmacy, Medical University Sofia, Sofia, Bulgaria.

Aims: Late-diagnosed diabetic retinopathy (DR) is difficult and expensive to treat. Screening programmes can identify the disease early and reduce the costs of its future treatment. This study aims to analyse the cost-benefit of screening programmes for DR.

View Article and Find Full Text PDF

Microalgae and their rich nutrient content are increasingly recognized as a sustainable food source. Microalgal macular pigment (MP), composed of zeaxanthin and lutein, is densely concentrated in the retinal macula of eyes and is frequently utilized in eye health maintenance. However, as a sustainable food ingredient, the food safety and functionality of MP need further investigated.

View Article and Find Full Text PDF

Objective: This study aims to evaluate the relationship between sodium-glucose cotransporter 2 inhibitors (SGLT2i) and diabetic retinopathy (DR) in diabetes mellitus.

Methods: We conducted a systematic search in PubMed, Embase, Cochrane Library, and ClinicalTrials.gov from their inception to November 9, 2024, for randomized controlled trials (RCTs) and real-world studies of SGLT2i in the treatment of diabetes mellitus.

View Article and Find Full Text PDF